Send to

Choose Destination
Clin Dev Immunol. 2012;2012:656340. doi: 10.1155/2012/656340. Epub 2012 Apr 29.

Programmed death ligand 2 in cancer-induced immune suppression.

Author information

Tumor Immunology Group, School of Medicine and Pharmacology, University of Western Australia, 4th Floor, G-block, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA 6009, Australia.


Inhibitory molecules of the B7/CD28 family play a key role in the induction of immune tolerance in the tumor microenvironment. The programmed death-1 receptor (PD-1), with its ligands PD-L1 and PD-L2, constitutes an important member of these inhibitory pathways. The relevance of the PD-1/PD-L1 pathway in cancer has been extensively studied and therapeutic approaches targeting PD-1 and PD-L1 have been developed and are undergoing human clinical testing. However, PD-L2 has not received as much attention and its role in modulating tumor immunity is less clear. Here, we review the literature on the immunobiology of PD-L2, particularly on its possible roles in cancer-induced immune suppression and we discuss the results of recent studies targeting PD-L2 in cancer.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center